ANGUS ACQUIRES EXPRESSION SYSTEMS, LLC
PR98730
BUFFALO GROVE, Ill. and DAVIS, Calif., Nov. 10, 2022 /PRNewswire=KYODO JBN/ --
-- Expression Systems is a leading supplier of innovative cell culture media,
baculovirus molecular reagents and cell lines used in advanced biological-based
therapeutics
ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer
and marketer of specialty ingredients for Life Sciences and Industrial markets,
today announced it has acquired Expression Systems, LLC (
) ("Expression Systems"), a leading global manufacturer of cell culture media
and related products and services. ANGUS is a portfolio company of Ardian and
Golden Gate Capital.
Logo - https://mma.prnewswire.com/media/460234/ANGUS_Chemical_Company_Logo.jpg
Founded in 1997, Expression Systems is dedicated to supplying and servicing the
baculovirus expression platform with innovative cell culture media
formulations, as well as cell lines, molecular tools, reagents and contract
services. Expression Systems operates from a central headquarters in Davis,
California, and is cGMP-compliant and ISO 13485 certified for its manufacturing
and research activities.
"The acquisition of Expression Systems is an important step in expanding ANGUS'
leadership position in Life Sciences beyond bio buffers into specialty cell
culture media, a strategic adjacency with high customer overlap and
complementary product and service offerings," said ANGUS President and Chief
Executive Officer David Neuberger. "The combination of ANGUS and Expression
Systems further strengthens our ability to deliver value through the
consistent, high-quality ingredients and services essential to all phases of
bioprocessing, from early-stage biologics development to full-scale commercial
production."
Expression Systems is a well-recognized independent provider of specialized
cell culture media and related products with a robust track record of product
quality and innovation based on proprietary technology. The company specializes
in baculovirus expression vector system (BEVS) and has deep expertise across
the process from gene optimization to protein purification. Expression Systems'
products are utilized primarily by structural biology researchers and biologics
manufacturers to produce certain drug candidates, protein-based therapies,
vaccines and gene therapies efficiently and cost-effectively.
"For more than 20 years, our family and dedicated employees have built a strong
reputation with its customers by leveraging our world-renowned technical
expertise in media manufacturing and the baculovirus expression platform," said
Expression Systems President and Chief Executive Officer David Hedin. "When we
looked ahead to the future for our company, it was clear that ANGUS was in the
best position to provide new opportunities to our current and new customers, as
well as our employees. ANGUS will enhance our position as a dedicated,
world-leading vendor focused on servicing the biologics industry segments
employing the baculovirus expression platform."
Achelous Partners, LLC served as exclusive M&A advisor to Expression Systems,
LLC on this transaction.
ABOUT ANGUS
ANGUS is a leading global manufacturer and marketer of specialty ingredients
and consumables for biotechnology, pharmaceutical, consumer and industrial
applications. The Company innovates through its unique nitroalkane chemistries,
including its flagship AMP(TM) (aminomethyl propanol) multifunctional additives
and TRIS AMINO(TM) (tromethamine) buffers, which are produced at fully
integrated, ISO 9001-certified manufacturing facilities in the United States
and Germany. ANGUS serves its global customers through six regional Customer
Application Centers located in Chicago, Illinois; Paris, France; Sao Paulo,
Brazil; Singapore; Shanghai, China; and Mumbai, India. The Company is privately
owned by Ardian and Golden Gate Capital, and is headquartered in Buffalo Grove,
Illinois. For more information, visit angus.com (
).
Follow ANGUS on Facebook (
), Twitter (
), and LinkedIn (
).
FOR ADDITIONAL INFORMATION
ANGUS Media Relations
Scott C. Johnson
+1 847-808-3769
scjohnson@angus.com
SOURCE: ANGUS Chemical Company
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。